2026-01-27 - Analysis Report
**Company Overview:** Procter & Gamble is a multinational consumer goods corporation that manufactures a diverse range of consumer goods.

**Comparison of Return Rates:**
- Review Stock (PG): 48.41%
- S&P 500 (VOO): 127.58%
- Divergence (current): -77.40
- Relative Divergence (current): 9.50%

**Analysis:** The review stock underperformed the S&P 500 in the given period by 77.40% cumulatively.

**Alpha, Beta Analysis:**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 13.0% | 10.9% | 5.0% | 0.5 | 214.8B |
| 2017-2019  | 42.0% | 10.9% | 17.0% | 0.5 | 291.9B |
| 2018-2020  | 54.0% | 21.9% | 30.0% | 0.7 | 325.1B |
| 2019-2021  | 58.0% | 21.9% | -6.0% | 0.7 | 382.2B |
| 2020-2022  | 10.0% | 21.9% | 5.0% | 0.6 | 354.2B |
| 2021-2023  | 4.0% | 19.5% | -14.0% | 0.4 | 342.4B |
| 2022-2024  | -6.0% | 19.5% | -35.0% | 0.4 | 391.8B |
| 2023-2025  | -8.0% | 16.0% | -83.0% | 0.2 | 334.9B |

**Analysis:** The review stock had varying performance in different periods, with a high of 58.0% CAGR and a low of -8.0% CAGR.

**Recent Stock Price Fluctuations:**
- Close: $149.49
- Last-market: $149.49
- Change: -0.44
- 5-day SMA: $148.53
- 20-day SMA: $144.30
- 60-day SMA: $145.43

**Analysis:** The review stock recently experienced a decline, with the 5-day SMA and 20-day SMA both lower than the current price.

**RSI, PPO, Delta_Previous and Expected_Return Analysis:**
- Market Risk Indicator (MRI): 0.70
- RSI: 72.11
- PPO: 0.64
- Hybrid Signal: Buy
- Risk Level: Medium
- Recent relative divergence change: +5.00 (improving)
- 7-day Rank change: -24 (rank down)
- 7-day Dynamic Expected Return change: -143.00 (worsening)
- Expected Return (%): -142.60%
- **Sharp rebound/sharp decline:** Recent fluctuations indicate a sharp decline.

**Analysis:** The review stock has a high RSI and PPO, indicating it may be overbought. The hybrid signal also indicates a buy signal, but the recent relative divergence change and 7-day Dynamic Expected Return change suggest a possible worsening of the performance.

**Recent News & Significant Events:**
- Insider Sale: Chief Brand Officer of $PG sells 95,903 shares.
- Procter & Gamble Company earnings top estimates, but shrinking demand weighs on sales.
- Procter & Gamble Company is attracting investor attention.
- PG stock tops Est√©e Lauder on core fundamentals.
- Will softer volumes and premium push in China change Procter & Gamble's narrative?

**Analysis:** The recent news suggests that the company is experiencing challenges in sales, but it is still attracting investor attention.

**Analyst Opinions:**
- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.96 (~Buy)
  - Opinions: 22
  - Target Price (avg/high/low): 167.18 / 186.00 / 148.00

**Analysis:** The analyst consensus suggests that the review stock is a buy, with a target price range of $148.00 to $186.00.

**Earnings Analysis:**
| Date | EPS | Revenue |
|---|---:|---:|
| 2026-01-23 | 1.82 | 22.21 B$ |
| 2025-10-24 | 2 | 22.39 B$ |
| 2025-04-24 | 1.58 | 19.78 B$ |
| 2025-01-22 | 1.94 | 21.88 B$ |

**Analysis:** The review stock's EPS has varied over the past periods, with a high of $2 and a low of $1.58. The revenue has also varied, with a high of $22.39 billion and a low of $19.78 billion.

**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $22.39B | 51.37% |
| 2025-06-30 | $20.89B | 49.11% |
| 2025-03-31 | $19.78B | 50.98% |
| 2024-12-31 | $21.88B | 52.39% |

**Analysis:** The review stock's revenue and profit margin have varied over the past periods, with a high profit margin of 52.39% and a low profit margin of 49.11%.

**Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $53.27B | 8.92% |
| 2025-06-30 | $52.01B | 6.95% |
| 2025-03-31 | $52.27B | 7.21% |
| 2024-12-31 | $51.17B | 9.05% |

**Analysis:** The review stock's equity has varied over the past periods, with a high of $53.27 billion and a low of $51.17 billion. The ROE has also varied, with a high of 9.05% and a low of 6.95%.

**Comprehensive Analysis:**
The review stock, Procter & Gamble, has had varying performance over the past periods. It underperformed the S&P 500 by 77.40% cumulatively, but had a high CAGR of 58.0% in one period. The stock recently experienced a decline, with the 5-day SMA and 20-day SMA both lower than the current price. The hybrid signal indicates a buy signal, but the recent relative divergence change and 7-day Dynamic Expected Return change suggest a possible worsening of the performance. The earnings analysis suggests that the EPS has varied over the past periods, with a high of $2 and a low of $1.58.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.